First-quarter profits down at Nycomed contrast media:
This article was originally published in Clinica
Norwegian contrast media and pharmaceuticals manufacturer Hafslund Nycomed has reported lower operating profits for its contrast media division. In the first quarter, profits declined 9% to NKr 553 million ($84 million). First-quarter turnover was down 4% to NKr 1,227 million. The company blames the decline on increased price pressure in the contrast agent market in the US. In March, Nycomed lost its position as preferred supplier to American Health Services (AMHS) (see Clinica No 700/1, p 20). Hafslund Nycomed's group sales in the first quarter were NKr 2,380 million and pre-tax income was NKr 456 million.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.